TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Decrease in distress score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of cervical dilatation advancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rate of angle of progression advancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Recapture of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute reduction in leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in WOMAC Knee Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patients' pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seroconversion rate of HI antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: seroprotection rate of HI antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT and GMI of HI antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to reach irreversible EDSS scores of 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in quality of life evaluated by EQ-5D-5L scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in quality of life evaluated by SF-12 scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average number of hairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-individual plasma biochemistry response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 Hour Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Kihon Checklist score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acceptability of Faslodex
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compliance with Faslodex
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated dose of arsenic trioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biologically effective dose of arsenic trioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and negative affects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in ECG readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participant's Perception of Physician's Compassion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy in untreated AML subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematological outcomes
Primary endpoint: Efficacy in refractory/relapsed AML subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematological outcomes
Primary endpoint: Sentinel lymph node detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: tolerability and safety of Influenza VLP Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: immunogenicity as measured by hemagglutination inhibition (HAI) antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of FG-3019
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients with stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Receiving Recommended Treatment Duration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency rate of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Expression of immunoregulatory cytokines by CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Helper T cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Regulatory T cell phenotype and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Major pathological response (MPR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to achieve recovery of GI function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Subjects With Drug-related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: White Blood Cell Phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the curve (AUC) in the interval of 0-6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With New Vertebral Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of Brivanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough observed plasma concentration (Cmin) of Brivanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to the end of the dosing interval [AUC(TAU)] of Brivanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants experiencing immediate treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing early treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing late treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Thiol Disulfide Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Rate of Moderate or Severe COPD Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient-reported health-related quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical Exacerbation of COPD (CE-COPD) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Correction of prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL) - MPN-SAF TSS; MPN-10
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in spleen size (or volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproductive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Area under the curve of salivary secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of acceptable glucose measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease of vascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Serum LRG measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue epithelialization speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time intragastric pH ≥ 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Concentration-time Curve of the Analyte in Plasma, Empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of the Analyte in Plasma, Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of the Analyte in Plasma, Empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of the Analyte in Plasma, Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative Myocardial Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful self-application of sunscreen
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Elbow appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of PK parameters following GSK2140944 administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of GSK2140944 as assessed by adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Lowering of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical well being via electrocardiogram and body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental well being via questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of heel pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum tolerated dose (MTD) of Gemcitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective burden score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relative Volume of Distribution of [F18]-FDDNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Unnoticed neoplasms requiring additional therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patients' subjective assessment of usability of the PRECIOUS system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with the PRECIOUS system
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: User's acceptance of the PRECIOUS system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in periocular region bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical Global Impression of Improvement (CGI-I) Responder Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adolescent Research Participant Assessment Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Caregiver Research Participant Assessment Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Superoxide anion levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Downregulation in glucagon-like immunoreactivity (GLI) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Freedom rate of stroke or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Patient clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau of tamsulosin OCAS in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau of solifenacin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of tamsulosin OCAS in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of solifenacin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Contracture to 5° or Less
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Height Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of apnea mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: KOOS Subscores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Kujala Anterior Knee Pain Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Medical Outcomes Study (SF-36) for generic quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occiput tissue pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of febrile neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Met Clinical Worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with HBsAg loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of hospitalisations for heart failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Composite VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Corrected count increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline steroid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Ethyl glucuronide concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Urine Ethyl sulfate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Dose-limiting Toxicity (DLT) Events
Endpoint domain: Adverse events/effects
Primary endpoint: episode of retinochoroiditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Incidence of respiratory tract infection episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Anxiety symptom
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: O2 desaturation measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in endothelial cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: absolute change in inflammatory lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4 cell count changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Donors Requiring a Second Collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Deglutition Handicap Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Primary AVF patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of MOVE! Visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Partial and complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of influenza-like illness (ILI)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of COVID-like illness (CLI)
Endpoint domain: Adverse events/effects
Primary endpoint: AUClast/D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax/D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paretic Step Width During Gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skin blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite of death and cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Acute coronary syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of occult asymptomatic cardiotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of annual exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement as measured by Asthma Control Test (ACT)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: TNF-α Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical status evaluated in agreement with guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic yield of PSG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: respiratory disturbance index at highest CPAP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in smoking status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in work-related activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes in social habits
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Total Body Bone Mineral Density (TBBMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: grade 2+ GU toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: initial antibiotic treatment failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: in-hospital clinical failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day post-discharge clinical failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Half life [t1/2]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average duration of exposure to PN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from major adverse events and radial access complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in number of dementia care process quality indicators achieved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of common cold
Endpoint domain: Adverse events/effects
Primary endpoint: Number of intravitreal anti-VEGF injections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bilateral isometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical and Functional Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevention of AOM caused by vaccine-type pneumococcus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bleeding loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse Events (AEs) including Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients with Abnormalities in Safety Laboratory Parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the electrocardiogram QT interval
Endpoint domain: Adverse events/effects
Primary endpoint: Immunologic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration - Time Curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline levels of cortisol in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline levels of heart-rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline scores of the subscale for Negative Mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in total score of Insomnia Severity Index (ISI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Sedentary Activity Duration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Casual Walking Duration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Patients With Serum PSA Levels ≤4.0 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oxygenation Parameter of P(A-a)O2 Gradient by Day 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Patients Who Have Been Intubated by Day 14
Endpoint domain: Adverse events/effects
Primary endpoint: Bupropion Plasma Concentrations/Area-Under-the-Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of online training module
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of patients experiencing dose-limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Microcephaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delay in development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chromogranin A (CgA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade ≥ 3 Stomatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in anti-oxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolite profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in size (patency of bile duct)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes